JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
type: channel
description: The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) was established in 2020 as the official vehicle for disseminating scientific information from the Brazilian Society of Bone Marrow Transplantation (Sociedade Brasileira de Terapia Celular e Transplante de Medula Óssea - SBTMO). The target audience is researchers, teachers, professionals and students with an interest in the medicine field, especially bone marrow transplantation, cell therapy and related sciences. Aiming to facilitate the immediate dissemination of articles, the Journal of Bone Marrow Transplantation and Cellular Therapy adopts a continuous publication model, with articles made available as soon as they are approved and are compiled into a single annual volume. The journal's abbreviated title is J Bone Marrow Transplant Cell Ther and should be used in bibliographies, footnotes, references and bibliographic captions. Focus and Scope The Journal of Bone Marrow Transplantation and Cellular Therapy publishes the results of basic and applied research that promotes scientific development in Hematology, Bone Marrow Transplantation, Cellular Therapy and related áreas. Open Access The Journal of Bone Marrow Transplantation and Cellular Therapy follows the Diamond Open Access model and authors or readers are not charged for any fees. The Journal of Bone Marrow Transplantation and Cellular Therapy offers immediate open access to its content, adhering to the principles of free access and the democratization of scientific knowledge. To maximize the dissemination and use of published material, the Journal of Bone Marrow Transplantation and Cellular Therapy adopts the Creative Commons license with CC BY 4.0 attribution. Thus, the copyright belongs to the authors, granting free and immediate access to the work and allowing any user to read, download, copy, distribute, print, search the full texts of the articles, or create links to them, crawl the articles for indexing, use them as data for soft…
publisher: Sociedade Brasileira de Transplante de Medula Óssea
language: en-US
publication name: JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
issn: 2675-374X
items: Non-infectious complications after hematopoietic cell transplantation
items: Management of pediatric acute leukemias relapse after hematopoietic cell transplantation
items: Sickle cell disease
items: Hematopoietic stem cell transplantation in children with thalassemia: Brazilian Society of Bone Marrow Transplantation Consensus
items: Hematopoietic cell transplantation in inherited bone marrow failure syndromes
items: Long-term follow-up after pediatric hematopoietic stem cell transplantation
items: Central nervous system tumors
items: Hematopoietic cell transplantation for all: report from the 2025 Congress of the Brazilian Bone Marrow Transplantation and Cellular Therapy Society
items: https://jbmtct.sbtmo.org.br/jbmtct/article/view/281
items: SEROLOGICAL STATUS OF EPSTEIN-BARR VIRUS IN BONE MARROW DONOR AND RECIPIENT AND ITS IMPACT ON POST-TRANSPLANT OUTCOMES
items: https://jbmtct.sbtmo.org.br/jbmtct/article/view/277
items: CURRENT USE AND OUTCOMES OF CELLULAR THERAPY: BRAZILIAN SUMMARY SLIDES -2025 ‎
items: Hematopoietic Cell Transplantation in Brazil: A National Benchmarking Study Focused on the Foundation for the Accreditation of Cellular Therapy (FACT) Performance Indicators
items: THE CIBMTR HEMATOPOIETIC CELL TRANSPLANT RECIPIENT TRANSFER TOOL FOR FOLLOW UP MAINTENANCE: ADHERENCE ASSESSMENT OF 24 BRAZILIAN CENTERS AND ONE URUGUAYAN
items: CURRENT USE AND OUTCOMES OF HEMATOPOIETIC CELL TRANSPLANTATION: BRAZILIAN SUMMARY SLIDES – 2025
items: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER: CLINICAL INSIGHTS AND REAL-WORLD ANALYSIS AT A SPECIALIZED CENTER IN NORTHEASTERN BRAZIL
items: Two cases of clump formation after thawing of hematopoietic progenitor cell products for transplantation
items: A case-control study on cryopreserved versus non-cryopreserved strategies for autologous hematopoietic cell transplantation in multiple myeloma
items: The role of the pharmacy navigator in hematopoietic stem cell transplantation
items: Immune reconstitution inflammatory syndrome in HIV-negative patients with hematological malignancies and hematopoietic stem cell transplantation: A case series and a literature review
items: Haploidentical Hematopoietic Stem-cell Transplant for High-Risk Acute Myeloid Leukemia in a Kidney Transplant Recipient: Case Report
items: The Effectiveness of the Multiprofessional Approach in the Pediatric Rehabilitation of Chronic GVHD: The Specific Contribution of Occupational Therapy
items: X linked- ALD: Should Loes score be the only benchmark for HSCT eligibility?
items: Updates on the management of Multiple Myeloma
items: Guidelines for the Diagnosis and Management of Paroxysmal Nocturnal Hemoglobinuria (PNH) at Hospital Universitário Walter Cantídio.

Non-infectious complications after hematopoietic cell transplantation
type: item
description: Hematopoietic cell transplantation (HCT) is a curative treatment for children with malignant and non-malignant diseases. In recent years, we have observed a significant increase in the survival of these patients, due to improved resources. In this article, we discuss non-infectious complications related to HCT, including their management, prevention, and best options of treatment.
creator: Gustavo Zamperlini
creator: Aline Ferrari Martins
creator: Barbara da Cunha Arantes e Silva
creator: Maite Freire Cardoso
creator: Analiz Marchini Rodrigues
creator: Thábata Cristina Paradas Moreira da Silva
creator: Ana Carolina Ferreira Castro Salum
creator: Adriana Seber
creator: Natalia Borges
creator: Alessandra Araujo Gomes
rights: Copyright (c) 2025 Gustavo Zamperlini, Aline Ferrari Martins, Barbara da Cunha Arantes e Silva, Maite Freire Cardoso, Analiz Marchini Rodrigues, Thábata Cristina Paradas Moreira da Silva, Ana Carolina Ferreira Castro Salum, Adriana Seber, Natalia Borges, Alessandra Araujo Gomes https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-10-29
publication date: 2025-10-29
volume: 6
number: 1
doi: 10.46765/2675-374X.2025v6n1e283

Management of pediatric acute leukemias relapse after hematopoietic cell transplantation
type: item
description: Prevention is the best way to avoid relapse after hematopoietic cell transplantation (HCT). Immunomodulation can enhance graft-versus-leukemia effect and, if graft-versus-host disease (GVHD) is absent, prophylactic donor lymphocyte infusion (DLI) may be indicated for high-risk patients. Maintenance strategies with blinatumomab, inotuzumab, tyrosine kinase inhibitors, hypomethylating agents or venetoclax can be effective in reducing relapse rates. However, maintenance therapy response depends on individual toxicity and physician’s experience in handle with dose adjustments, undesirable drug interactions and complications. Preemptive approach guided by minimal residual disease (MRD) or mixed chimerism is fundamental to prevent hematologic relapse. Target agent or immunotherapy followed by DLI can be used, and if no response, low-dose chemotherapy can be added to reach disease control. After relapse, antigen-directed therapies with blinatumumab for CD19 ALL and inotuzumab for CD22 ALL are good options to induce MRD negativity and bridge to second HCT. Emerging therapies like daratumumab, immune checkpoint or menin inhibitors are promising but require validation. CAR-T cell therapy can provide a better chance of long-term survival if low leukemia burden and absence of GVHD. It is also effective in extramedullary disease, mainly in central nervous system relapse. Patients with B-cell aplasia loss after CAR T-cell therapy are second transplant candidates, as well as those with acute myeloid leukemia who respond to salvage therapy. Second HCT outcomes are better if relapse occurred ≥ 12 months after the first HCT. Strategies for expanding access to immunotherapy and target agents are crucial to improve long-term survival in these children.
creator: Rita de Cássia Barbosa Tavares
creator: Polliany Roberta Dorini Pelegrina
creator: Carla Nolasco Monteiro Breviglieri
creator: Ana Luiza de Mello Rodrigues
creator: Gustavo Zamperlini
creator: Adriana Martins de Sousa
creator: Patricia Regina Cavalcanti Barbosa Horn
creator: Luiz Guilherme Darrigo Jr
creator: Liane Daudt
rights: Copyright (c) 2025 Rita de Cássia Barbosa Tavares, Polliany Roberta Dorini Pelegrina, Carla Nolasco Monteiro Breviglieri, Ana Luiza de Mello Rodrigues, Gustavo Zamperlini, Adriana Martins de Sousa, Patricia Regina Cavalcanti Barbosa Horn, Luiz Guilherme Darrigo Jr, Liane Daudt https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-10-20
publication date: 2025-10-20
volume: 6
number: 1
doi: 10.46765/2675-374X.2025v6n1e285

Sickle cell disease
type: item
description: Sickle cell disease (SCD) is known as the most common hemoglobin disorder, with severe forms of thalassemia syndromes following closely. Current standard treatments, including transfusions, hydroxyurea, and L-glutamine, still do not significantly improve life expectancy and quality of life for patients. Allogeneic hematopoietic cell transplantation (HCT) remains the only curative option, showing overall survival and event-free survival rates over 90%, especially in patients under 16 years old. However, only 15% of SCD patients have access to an unaffected family donor. To increase donor availability, alternative sources such as matched unrelated donors, unrelated umbilical cord blood, and haploidentical donors have become viable options for patients without a matched related donor. The aim of this article was to update the Brazilian consensus previously published by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, highlighting the latest developments in the treatment and monitoring of patients with SCD undergoing HCT.
creator: Luiz Guilherme Darrigo Junior
creator: Roseane Vasconcelos Gouveia
creator: Cilmara Kuwahara
creator: Alexandre de Albuquerque Antunes
creator: Adriana Martins de Sousa
creator: Ana Karine Vieira
creator: Ainá Henriques Melgaço
creator: Juliana Folloni Fernandes
creator: Adriana Seber
rights: Copyright (c) 2025 Luiz Guilherme Darrigo Junior, Roseane Vasconcelos Gouveia, Cilmara Kuwahara, Alexandre de Albuquerque Antunes, Adriana Martins de Sousa , Ana Karine Vieira, Ainá Henriques Melgaço, Juliana Folloni Fernandes, Adriana Seber https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-10-20
publication date: 2025-10-20
volume: 6
number: 1
doi: 10.46765/2675-374X.2025v6n1e294

Hematopoietic stem cell transplantation in children with thalassemia: Brazilian Society of Bone Marrow Transplantation Consensus
type: item
description: Allogeneic hematopoietic cell transplantation (HCT) represents a critical therapeutic option for patients with transfusiondependent thalassemia (TDT), with thalassemia-free survival rates exceeding 90% in cases involving HLA-matched sibling donors. Due to the limited availability of matched donors, alternative sources such as HLA-matched unrelated donors, haploidentical donors, and umbilical cord blood have broadened HCT eligibility. Despite its potential for cure, HCT involves risks like graft-versus-host disease, graft rejection, and transplant-related mortality. Recent improvements in conditioning regimens have enhanced patient outcomes and quality of life. Factors affecting HCT success in TDT include recipient age, disease complications, effective chelation therapy, Pesaro score, and donor compatibility. This article aimed to update the Brazilian consensus established by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, incorporating the latest advances in treating and managing TDT patients undergoing transplantation.
creator: Luiz Guilherme Darrigo Junior
creator: Ana Karine Vieira
creator: Cilmara Kuwahara
creator: Roseane Vasconcelos Gouveia
creator: Paulo Klinger
creator: Alexandre de Albuquerque Antunes
creator: Julia Lopes Garcia
rights: Copyright (c) 2025 Luiz Guilherme Darrigo Junior, Ana Karine Vieira, Cilmara Kuwahara, Roseane Vasconcelos Gouveia, Paulo Klinger, Alexandre de Albuquerque Antunes, Julia Lopes Garcia https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-10-23
publication date: 2025-10-23
volume: 6
number: 1
doi: 10.46765/2675-374X.2025v6n1e292

Hematopoietic cell transplantation in inherited bone marrow failure syndromes
type: item
description: Inherited bone marrow failure syndromes (IBMFS) comprise a heterogeneous group of rare genetic disorders characterized by defective hematopoiesis, congenital anomalies, and a predisposition to clonal evolution and malignancies. Hematopoietic cell transplantation remains the only curative option for the hematologic manifestations of these disorders, although it does not correct congenital malformations or eliminate the long-term risk of non-hematopoietic cancers. This review summarized current evidence and transplantation strategies for major IBMFS, including Fanconi anemia, dyskeratosis congenita/telomere biology disorders, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, congenital neutropenia, congenital amegakaryocytic thrombocytopenia, and other inherited thrombocytopenias. We discussed disease-specific transplant indications, donor selection, conditioning regimens, graft source preferences, and outcomes across different patient populations. Advances in reduced-intensity conditioning and post-transplant cyclophosphamide have expanded donor availability, improving survival even with alternative donors. Nevertheless, long-term challenges persist, such as increased risks of solid tumors, endocrine dysfunction, and organ toxicity, emphasizing the need for multidisciplinary care and lifelong surveillance. Optimal outcomes depend on timely referral to specialized centers, meticulous donor screening, and individualized transplant strategies tailored to the unique biology of each disorder.
creator: Gisele Loth
creator: Luiz Guilherme Darrigo Júnior
creator: Adriana Martins de Sousa
creator: Alexandre de Albuquerque Antunes
creator: Ana Karine Vieira
rights: Copyright (c) 2025 Gisele Loth, Luiz Guilherme Darrigo, Adriana Martins, Alexandre de Albuquerque Antunes, Ana Karine Vieira https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-10-18
publication date: 2025-10-18
volume: 6
number: 1
doi: 10.46765/2675-374X.2025v6n1e288

Long-term follow-up after pediatric hematopoietic stem cell transplantation
type: item
description: This article, part of the Pediatric Group consensus of the Brazilian Society of Bone Marrow Transplantation, addresses lifelong follow-up in pediatric hematopoietic stem cell transplant survivors. With the growing number of long-term survivors, specialized monitoring is essential, especially for high-risk groups such as infants, recipients of total body irradiation, and those with inherited bone marrow failure syndromes. The consensus outlines surveillance strategies for detecting and managing late complications, including chronic graft-versus-host disease and secondary effects. Multidisciplinary recommendations aim to optimize early intervention and quality of life, establishing a standardized follow-up framework for pediatric transplant care in Brazil.
creator: Polliany Roberta Dorini Pelegrina
creator: Roseane Vasconcelos Gouveia
creator: Antonio Vaz de Macedo
creator: Ana Karine Vieira
creator: Gabriela Gaspar Filgueiras Landi
creator: Julia Lopes
creator: Osvaldo Alves de Menezes Neto
creator: Rafaela de Souza Ferreira
creator: Adriana Aparecida Siviero Miachon
creator: Rita de Cássia Barbosa da Silva Tavares
creator: Carmem Bonfim
rights: Copyright (c) 2025 Polliany Roberta Dorini Pelegrina, Roseane Vasconcelos Gouveia , Antonio Vaz de Macedo, Ana Karine Vieira, Gabriela Gaspar Filgueiras Landi, Julia Lopes, Osvaldo Alves de Menezes Neto, Rafaela de Souza Ferreira, Adriana Aparecida Siviero Miachon, Rita de Cássia Barbosa da Silva Tavares , Carmem Bonfim https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-10-18
publication date: 2025-10-18
volume: 6
number: 1
doi: 10.46765/2675-374X.2025v6n1e286

Central nervous system tumors
type: item
description: Central nervous system (CNS) tumors represent one of the most prevalent groups of neoplasms in the pediatric population. Recent advances in molecular biology and neuro-oncology have led to continuous updates in the classification of these tumors, which poses significant diagnostic challenges, particularly in low- and middle-income countries, with limited access to advanced diagnostic tools. The therapeutic approach varies according to tumor subtype, often requiring complex and resource-intensive protocols. One such strategy involves the use of high-dose chemotherapy followed by autologous stem cell rescue, which has shown promise in improving outcomes for select pediatric patients with CNS tumors. However, implementation of this therapy in countries like Brazil faces logistical, financial, and clinical practice challenges. This article aimed to provide a brief overview and suggestions to use high-dose chemotherapy with autologous stem cell transplantation in the treatment of pediatric CNS tumors. We discussed practical considerations for patient selection, and conditioning regimens. Our objectives were to optimize and guide current practices by proposing strategies that maybe feasible in the Brazilian public and private healthcare systems.
creator: Gustavo Zamperlini
creator: Paulo Henrique dos Santos Klinger
creator: Antonella Zanette
creator: Cilmara Kuwahara
creator: Sidnei Epelman
creator: Adriana Seber
creator: Cláudio Galvão de Castro Junior
rights: Copyright (c) 2025 Gustavo Zamperlini, Paulo Henrique dos Santos Klinger, Antonella Zanette, Cilmara Kuwahara, Sidnei Epelman, Adriana Seber, Cláudio Galvão de Castro Junior https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-10-18
publication date: 2025-10-18
volume: 6
number: 1
doi: 10.46765/2675-374X.2025v6n1e284

Hematopoietic cell transplantation for all: report from the 2025 Congress of the Brazilian Bone Marrow Transplantation and Cellular Therapy Society
type: item
description: This article provides an analysis of the current landscape of hematopoietic cell transplantation (HCT) in Brazil, highlighting current data, challenges, and ongoing initiatives, as presented at the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO) 2025 meeting. Brazil has seen a significant increase in the number of HCT procedures in recent years, being the country with the highest number of transplants, HCT centers, and transplant teams in Latin America. However, important challenges remain, including regional disparities in access, limited local availability of HCT, and insufficient hospital beds. These topics were discussed alongside partial updates of the new National Transplant System (SNT) regulations with representatives from SBTMO, SNT, Brazilian Health Regulatory Agency, Brazilian National Cancer Institute, Brazilian Association of Lymphoma and Leukemia, and Brazilian Association of Hematology, Hemotherapy, and Cellular Therapy, to improve equity, safety, and outcomes of hematopoietic stem cell transplants across Brazil.
creator: Fernando Barroso Duarte
creator: Andresa Lima Melo
creator: Adriano Arantes
creator: Carmem Maria Sales Bonfim
rights: Copyright (c) 2025 Fernando Barroso Duarte, Andresa Lima Melo, Adriano Arantes, Carmem Maria Sales Bonfim https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-10-21
publication date: 2025-10-21
volume: 6
number: 1
doi: 10.46765/2675-374X.2025v6n1e310

https://jbmtct.sbtmo.org.br/jbmtct/article/view/281
type: item
title: Development of a data manager support manual for hematopoietic cell transplantation and cellular therapy for Latin America: an innovative approach to data reporting to the Center for International Blood & Marrow Transplant Research
description: The Brazilian Hematopoietic Cell Transplantation and Cellular Therapy (HCT-CT/BR) Registry depends on data manager (DM) training to ensure sustainability, for which it is essential to standardize processes. The objectives of this study were to describe the development of a support manual for Brazilian DMs reporting to the Center for International Blood and Marrow Transplant Research and to present quality assessment results. The descriptive study (Feb–Aug 2024) included structuring, content creation, and dissemination of the manual. Survey assessed satisfaction. The manual was launched at the XXVIII Brazilian Society of Cellular Therapy and Bone Marrow Transplantation Congress. Thirty-nine professionals rated it 9.3/10 for satisfaction and 9.4/10 for recommendation. A manual is crucial for standardizing processes and ensuring data quality, offering clear and up-to-date guidance.
creator: Flavia Ferreira da Costa
creator: Paula Moreira da Silva Sabaini
creator: Cinthya Muniz Corrêa Rocha da Silva
creator: Anderson João Simeone
creator: Heliz Regina Alves das Neves
creator: Monique Ammi
creator: Rosana Rocha Batista Concilio
creator: Afonso Celso Vigorito
creator: Eliana Cristina Martins Miranda
creator: Leonardo Jun Otuyama
creator: Joaquim Gasparini dos Santos
creator: Mariza Toledo
creator: Adriana Mendes de Quadros Cavilha
creator: Jessica Di Chiara Salgado
creator: Eudoxiana Melo
creator: Simone Ojima Ferreira
creator: Antonio Vaz Macedo
creator: Adriana Seber
creator: Carmem Maria Sales Bonfim
creator: Vaneuza Araújo Moreira Funke
creator: Marcelo Pasquini
creator: Mary Flowers
creator: Nelson Hamerschlak
creator: Fernando Barroso Duarte
rights: Copyright (c) 2025 Flavia Ferreira da Costa, Paula Moreira da Silva Sabaini, Cinthya Muniz Corrêa Rocha da Silva, Anderson João Simeone, Heliz Regina Alves das Neves, Monique Ammi, Rosana Rocha Batista Concilio, Afonso Celso Vigorito, Eliana Cristina Martins Miranda, Leonardo Jun Otuyama, Joaquim Gasparini dos Santos, Mariza Toledo, Adriana Mendes de Quadros Cavilha, Jessica Di Chiara Salgado, Eudoxiana Melo, Simone Ojima Ferreira, Antonio Vaz Macedo, Adriana Seber, Carmem Maria Sales Bonfim, Vaneuza Araújo Moreira Funke, Marcelo Pasquini, Mary Flowers, Nelson Hamerschlak, Fernando Barroso Duarte https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-10-26
publication date: 2025-10-26
volume: 6
number: 1
doi: 10.46765/2675-374X.2025v6n1e281

SEROLOGICAL STATUS OF EPSTEIN-BARR VIRUS IN BONE MARROW DONOR AND RECIPIENT AND ITS IMPACT ON POST-TRANSPLANT OUTCOMES
type: item
description: The Epstein-Barr virus (EBV) is a highly immunogenic herpesvirus that infects more than 90% of healthy individuals and can remain latent in B lymphocytes for years. In this context, in immunocompromised patients, such as those undergoing bone marrow transplantation (BMT), viral reactivation can occur in up to 63% of cases. Among the main risk factors for viral reactivation are donor-recipient incompatibility, EBV IgG-positive donors, and conditioning regimens using lymphodepleting drugs such as anti-thymocyte immunoglobulin, high-dose cyclophosphamide, and corticosteroids. Therefore, weekly EBV monitoring is recommended during the first 100 days post-transplant to detect viremia early and enable preemptive intervention, either by reducing immunosuppression or using anti-CD20 monoclonal antibodies. These strategies aim to reduce viremia progression and the incidence of post-transplant lymphoproliferative disease (PTLD). This study seeks to estimate the serological profile of bone marrow donors and recipients and its relationship with the incidence of post-BMT viral reactivation. Additionally, it aims to evaluate monitoring and preemptive treatment strategies for managing high-risk patients at the Walter Cantídio University Hospital from 2020 to 2024, while also defining the incidence of PTLD secondary to BMT. Keywords: Bone Marrow Transplantation, Epstein Barr Virus, EBV, lymphoma
creator: Ana Vitória CHAVES
creator: HERCULES AMORIM MOTA SEGUNDO
creator: Sarah Emanuelle Viana Campos
creator: Fernando Barroso Duarte
creator: Karine Sampaio Nunes Barroso
rights: Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-05-20
publication date: 2025-05-20
volume: 6
number: 1
starting page: 260
ending page: 260
doi: 10.46765/2675-374X.2025v6n1p260

https://jbmtct.sbtmo.org.br/jbmtct/article/view/277
type: item
title: History of the Brazilian Cellular Therapy Processing Group and initial survey on cellular therapy processing, quality control, and release criteria for cryopreserved peripheral blood stem cells in autologous transplantation
description: There is considerable heterogeneity in peripheral blood stem cell (PBSC) cryopreservation protocols. In 2021, the Brazilian Cellular Therapy Processing Group was created to meet the need for technical specialists to exchange experiences, improve processes, and pursue international accreditation. This survey was developed to better understand national PBSC cryopreservation practices and to support the group’s technical discussions. An online questionnaire was created using Google Forms and disseminated. A total of 61 cell processing centers (CPC) responded to the survey. Most CPC showed interest in voluntary technical accreditation (n = 45; 73.8%), served one or two bone marrow transplantation units (n = 46; 75.4%) and processed bone marrow, PBSC and lymphocytes (n = 21; 34.4%). PBSCs were mainly cryopreserved within 24 hours of collection (n = 45; 73.8%), using a cryopreservation solution containing 5% DMSO and hydroxyethyl starch (n = 35; 67.3%). Most institutions froze and stored the cells at -80ÅãC until therapeutic use (n = 42; 80.8%). The maximum concentration of nucleated cells after cryopreservation varied widely across CPC. CD34+ cell quantification was most performed using the International Society for Hematotherapy and Graft Engineering dual-platform method (n = 25; 48.1%). The most frequently used post-cryopreservation quality control test was cell viability assessment using trypan blue exclusion (n = 34; 66.7%). This survey revealed considerable heterogeneity in PBSC cryopreservation practices among Brazilian CPC at the time the Cellular Therapy Processing Group was established. Since then, the group’s meetings have promoted improvements in the quality, safety, and efficacy of cell therapy products, as well as the gradual standardization of practices among its members.
creator: Karen de Lima Prata
creator: Andrea Tieme Kondo
creator: Brian Custer
creator: André Rolim Belisário
rights: Copyright (c) 2025 Karen de Lima Prata, Andrea Tieme Kondo , Brian Custer , André Rolim Belisário https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-10-07
publication date: 2025-10-07
volume: 6
number: 1
doi: 10.46765/2675-374X.2025v6n1e277

CURRENT USE AND OUTCOMES OF CELLULAR THERAPY: BRAZILIAN SUMMARY SLIDES -2025 ‎
type: item
description: Chimeric antigen receptor T-cells (CAR T cells) are genetically modified cellular immunotherapies approved as a standard of care treatment for patients with lymphoma and leukemia worldwide. Here, we report the initial activity in Brazilian centers through the collaboration between the Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) and the Center for International Blood and Marrow Transplant Research (CIBMTR). A total of 104 patients who received commercial and academic CAR-T cells in Brazil between January 2020 and April 2025 were included. The median age was 56 years (range 4-83). Indications were Non-Hodgkin Lymphoma (NHL; 75 cases; 72%), Acute Lymphoblastic Leukemia (ALL; 23 cases; 22%), Multiple Myeloma (MM; 4 cases; 4%) and Chronic lymphoblastic leukemia (CLL; 2 cases; 2%). Anti-CD19 commercial CAR-T were 82% of the total, 68 for NHL and 17 for ALL). Most deaths were due to disease progression or relapse (n=19), followed by infections (n=8). The overall survival after a median follow-up of 200 days was 73% (95% CI: 62-86; N=63) for NHL and 79% (95% CI: 63-99; N=19) for ALL. This report demonstrates the successful initial implementation of CAR-T cells in Brazil among centers that report to the SBTMO/CIBMTR. This infrastructure will assist in further capturing the activity, assessing the outcomes, and complying with regulatory requirements.
creator: Cinthya Corrêa da Silva
creator: Anderson João Simione
creator: Paula Moreira da Silva Sabaini
creator: Antonio Vaz Macedo
creator: Heliz Regina Alves das Neves
creator: Monique Ammi
creator: Flavia Ferreira da Costa
creator: Celso Arrais Rodrigues
creator: Adriana Mendes de Quadros Cavilha
creator: Rosana Rocha Concilio
creator: Phillip Scheinberg
creator: Nelson Hamerschlak
creator: Marco Aurelio Salvino
creator: Adriana Seber
creator: Yana Augusta Sarkis Novis
creator: Vanderson Geraldo Rocha
creator: Joaquim Gasparini
creator: Lúcia Silla
creator: Ricardo Chiattone
creator: Andreza Alice Feitosa Ribeiro
creator: Vaneuza Araújo Moreira Funke
creator: Leonardo Javier Arcuri
creator: Lucila Nassif Kerbauy
creator: Jayr Schmidt Filho
creator: Maria Claudia Rodrigues Moreira
creator: Carmem Maria Sales Bonfim
creator: Cilmara Cristina Kuwahara
creator: Marcelo C. Pasquini
creator: Fernando Barroso Duarte
rights: Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-07-04
publication date: 2025-07-04
volume: 6
number: 1
starting page: 271
ending page: 271
doi: 10.46765/2675-374X.2025v6n1p271

Hematopoietic Cell Transplantation in Brazil: A National Benchmarking Study Focused on the Foundation for the Accreditation of Cellular Therapy (FACT) Performance Indicators
type: item
description: Systematic evaluation of hematopoietic cell transplantation (HCT) outcomes is essential to improve clinical practice and meet international quality standards. In Brazil, the partnership between the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO) and the Center for International Blood and Marrow Transplant Research (CIBMTR) has advanced national data reporting and benchmarking through the Hematopoietic Cell Transplantation Brazilian Registry (HCTBR). This study reports outcomes from 11,210 first HCTs (5,984 allogeneic; 5,226 autologous) performed between 2012 and 2023 across 44 Brazilian centers. Median recipient age was 29 years for allogeneic and 53 years for autologous transplants. Acute leukemias predominated among allogeneic cases, while multiple myeloma was the most common indication for autologous HCT. Two-year overall survival was 82.0% for autologous and 59.8% for allogeneic transplants, with variation by donor type (matched related 61.8%, mismatched related 54.0%, unrelated 63.3%). Two-year non-relapse mortality was 8.0% and 21.6% for autologous and allogeneic transplants, respectively. The cumulative incidence of grade II–IV acute graft-versus-host disease (GVHD) at two years was 29.9%, with chronic GVHD incidence of 29.5%. Two-year relapse incidence was 24.1% for allogeneic and 25.8% for autologous HCT. Despite challenges within the Brazilian healthcare system, these outcomes align with international registry data. Adequate data completeness supports the robustness of these findings. Our results highlight the quality of Brazilian transplant programs and underscore the value of standardized outcome monitoring to foster continuous improvement. Strengthening center participation, follow-up, and data management remains critical to maintaining registry quality and enhancing patient care.
creator: Anderson João Simione
creator: Cinthya Silva
creator: Afonso Vigorito
creator: Antonio Macedo
creator: Heliz Neves
creator: Paula Sabaini
creator: Monique Ammi
creator: Flavia Costa
creator: Adriana Cavilha
creator: Rosana Concilio
creator: Vergilio Colturato
creator: Phillip Scheinberg
creator: Samir Nabhan
creator: Decio Lerner
creator: Nelson Hamerschlak
creator: Marcos Colella
creator: George Barros
creator: Alexandre Silvério
creator: Adriana Seber
creator: Simone Ferreira
creator: Yana Novis
creator: Joaquim Gasparini
creator: Vanderson Rocha
creator: Maria Moreira
creator: Claudia Astigarraga
creator: Liane Daudt
creator: Maria Macedo
creator: Ricardo Chiattone
creator: Juliana Fernandes
creator: Volney Vilela
creator: Rodolfo Soares
creator: Gustavo Teixeira
creator: Celso Rodrigues
creator: Roberto Silva
creator: Vaneuza Funke
creator: Leonardo Arcuri
creator: Jayr Filho
creator: Vinicius Molla
creator: João Farias
creator: Ricardo Pasquini
creator: Carmem Bonfim
creator: Abrahão Neto
creator: Rodolfo Calixto
creator: João Feliciano
creator: Rafael Gaiolla
creator: Marcelo Capra
creator: Angelo Atalla
creator: Milton Aranha
creator: Rony Schaffel
creator: Gianne Veloso
creator: Gustavo Bettarello
creator: Andresa Melo
creator: Simone Franco
creator: Marcelo Aduan
creator: Mary Flowers
creator: Marcelo Pasquini
creator: Fernando Duarte
rights: Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-07-02
publication date: 2025-07-02
volume: 6
number: 1
starting page: 270
ending page: 270
doi: 10.46765/2675-374X.2025v6n1p270

THE CIBMTR HEMATOPOIETIC CELL TRANSPLANT RECIPIENT TRANSFER TOOL FOR FOLLOW UP MAINTENANCE: ADHERENCE ASSESSMENT OF 24 BRAZILIAN CENTERS AND ONE URUGUAYAN
type: item
description: Introduction: Hematopoietic Cell Transplantation (HCT) remains a curative treatment for several malignant and non-malignant hematologic diseases. Despite significant advances in the field, maintaining long-term clinical follow-up continues to be a major challenge. To enhance continuity of care, the Center for International Blood and Marrow Transplant Research (CIBMTR) developed the patient transfer tool within FormsNet3, allowing the transfer of CRID identifiers between affiliated centers. However, little is known about the extent of adherence to this tool among South American centers. Objective: To evaluate the adherence of South American centers to the CIBMTR patient transfer tool, aiming to identify gaps and opportunities to improve data completeness and patient monitoring after HCT. Methods: An electronic questionnaire was distributed to South American centers actively participating in the CIBMTR, with at least 12 consecutive months of data reporting. The survey collected information on institutional characteristics, transplant volume, and experience with the CRID transfer tool. Data were analyzed using descriptive statistics and visualized through the Power BI platform. Results: Twenty-five centers participated in the study, representing 49% of active South American centers in the CIBMTR, of which 96% were Brazilian. Most centers were located in the Southeast region (70.8%) and included a variety of institutional types: private (44%), public (36%), and mixed (20%) hospitals. Regarding experience with the transfer tool, 60% of centers reported transferring patients, accounting for 67 movements (32 sendings and 35 receivings), predominantly involving adult patients undergoing allogeneic transplants. An asymmetric transfer pattern was observed: public centers primarily received transferred patients, whereas private centers were the main origin centers. Conclusion: Although the CIBMTR CRID-patient transfer tool represents a significant advancement in promoting long…
creator: Luiz Carlos da Costa-Junior
creator: Cinthya Corrêa da Silva
creator: Anderson João Simione
creator: Monique Ammi
creator: Marina Izu
creator: Paula Moreira da Silva Sabaini
creator: Jessica Di Chiara Salgado
creator: Antônio Vaz de Macedo
creator: Heliz Regina Alves das Neves
creator: Bruna Letícia da Silva Santos Geraldo
creator: Flavia Ferreira Costa
creator: Valeria Viana
creator: Adriana Mendes de Quadros Cavilha
creator: Rosana Rocha Concilio
creator: Nelson Hamerschlak
creator: Vergilio Antonio Rensi Colturato
creator: Sebastian Galeano
creator: Carmem Maria Sales Bonfim
creator: Marcelo Pasquini
creator: Mary Flowers
creator: Fernando Barroso Duarte
rights: Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-06-27
publication date: 2025-06-27
volume: 6
number: 1
starting page: 267
ending page: 267
doi: 10.46765/2675-374X.2025v6n1p267

CURRENT USE AND OUTCOMES OF HEMATOPOIETIC CELL TRANSPLANTATION: BRAZILIAN SUMMARY SLIDES – 2025
type: item
description: The development of the Brazilian Registry of Hematopoietic Cell Transplantation (HCT) in collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR) continues to provide a comprehensive assessment of the activity and general outcomes of HCT in Brazil. In this paper, we report an update of such activity. Brazilian transplant centers report their data to the CIBMTR, using the FormsNet3 platform. The data then return to the Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) through the Data Back to Centers (DBtC) tool. Data from patients who received an HCT from 2012 to 2024 from Brazilian centers were extracted from the CIBMTR. A descriptive analysis was carried out using patient, disease and transplant-specific variables and overall survival analysis using the Kaplan Meier method. A total of 14,331 patients were eligible for this study (6,583 autologous and 7,748 allogeneic HCTs). The number of reporting centers increased from 40 to 45 during the period. The most common HCT indication in Brazil for allogeneic HCT was AML, with 171 HCTs per year and, for autologous HCT, multiple myeloma, with 273 HCTs per year. Among allogeneic HCT, in the last 4 years, mismatched related donor was the main source of donors. Regarding the graft source for allogeneic HCTs, bone marrow (BM) was the most frequent among pediatric HCTs, while peripheral blood (PB) was the most used in adults. Infections were the leading cause of death in the first 100 days after all types of HCTs. Patients with acute leukemia who underwent HCT at an advanced disease stage had lower survival rates compared to those at earlier stages. Despite the differences in the number of cases and follow-up time, the results in this study were similar to those presented in the United States (USA) Summary Slides.
creator: Anderson João Simione
creator: Cinthya Silva
creator: Afonso Vigorito
creator: Antonio Vaz Macedo
creator: Heliz Regina Alves das Neves
creator: Paula Moreira da Silva Sabaini
creator: Monique Ammi
creator: Flavia Ferreira da Costa
creator: Adriana Mendes de Quadros Cavilha
creator: Rosana Rocha Concilio
creator: Vergilio Antonio Rensi Colturato
creator: Phillip Scheinberg
creator: Samir Kanaan Nabhan
creator: Decio Lerner
creator: Nelson Hamerschlak
creator: Marcos Paulo Colella
creator: George Maurício Navarro Barros
creator: Alexandre Silvério
creator: Adriana Seber
creator: Simone Ojima Ferreira
creator: Yana Augusta Sarkis Novis
creator: Joaquim Gasparini
creator: Vanderson Geraldo Rocha
creator: Maria Claudia Rodrigues Moreira
creator: Claudia Caceres Astigarraga
creator: Liane Esteves Daudt
creator: Maria Cristina Martins de Almeida Macedo
creator: Ricardo Chiattone
creator: Juliana Folloni Fernandes
creator: Volney Assis Lara Vilela
creator: Rodolfo Daniel de Almeida Soares
creator: Gustavo Machado Teixeira
creator: Celso Arrais- Rodrigues
creator: Roberto Luiz da Silva
creator: Vaneuza Araújo Moreira Funke
creator: Leonardo Javier Arcuri
creator: Jayr Schmidt Filho
creator: Vinicius Campos de Molla
creator: João Samuel de Holanda Farias
creator: Ricardo Pasquini
creator: Carmem Maria Sales Bonfim
creator: Abrahão Elias Hallack Neto
creator: Rodolfo Froes Calixto
creator: João Victor Piccolo Feliciano
creator: Rafael Dezen Gaiolla
creator: Marcelo Capra
creator: Angelo Atalla
creator: Milton Alexandre Ferreira Aranha
creator: Rony Schaffel
creator: Gianne Donato Costa Veloso
creator: Gustavo Bettarello
creator: Andresa Lima Melo
creator: Simone de Castro Resende Franco
creator: Marcelo Alves Aduan
creator: Mary Flowers
creator: Marcelo C. Pasquini
creator: Fernando Barroso Duarte
rights: Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-05-31
publication date: 2025-05-31
volume: 6
number: 1
starting page: 259
ending page: 259
doi: 10.46765/2675-374X.2025v6n1p259

POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER: CLINICAL INSIGHTS AND REAL-WORLD ANALYSIS AT A SPECIALIZED CENTER IN NORTHEASTERN BRAZIL
type: item
description: Post-Transplant Lymphoproliferative Disorders (PTLD) comprise a heterogeneous group of lymphoid or plasmacytic neoplasms with highly variable presentations, occurring in the setting of immunosuppression following transplantation. Epstein-Barr virus (EBV)-positive PTLD accounts for 60–80% of cases. Due to the rarity of the disease, no phase 3 clinical trials have been conducted to establish standardized treatment protocols, making its management particularly challenging. Objective: to characterize the profile of patients diagnosed with PTLD following kidney, liver, or hematopoietic stem cell transplantation at a specialized center in Northeastern Brazil. Methodology: a retrospective, observational, and single-center cohort study based on medical record analysis. Results: The analysis of the frequency of PTLD by transplanted organ group showed 3.7 cases per 1000 hematopoietic stem cell transplants, 7.0 cases per 1000 kidney transplants and 7.5 cases per 1000 liver transplants. The mean survival time for all patients was 438 days. Patients who achieved complete response had a better overall survival (OS) of 87.5% at 1 year, while those who did not achieve complete response had an OS of 22.2% at 1 year (p=0.00012). Conclusion: PTLD is commonly an aggressive disease with poor OS, possibly influenced by factors such as age, transplanted organ, comorbidities, early death, and delayed diagnosis. Keywords: Post-transplant lymphoproliferative disorder, Epstein-Barr virus, solid organ transplantation, hematopoietic stem cell transplantation.
creator: Thays Araújo Freire de Sá
creator: Hércules Amorim Mota Segundo
creator: Guilherme Rodrigues da Silva
creator: Laís Chaves Maia
creator: Mariana Saraiva Bezerra Alves
creator: Elodie Bomfim Hyppolito
creator: Paula Frassinetti Castelo Branco Camurça Fernandes
creator: Cláudia Maria Costa de Oliveira
creator: José Huygens Parente Garcia
creator: Fernando Barroso Duarte
rights: Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-07-04
publication date: 2025-07-04
volume: 6
number: 1
starting page: 258
ending page: 258
doi: 10.46765/2675-374X.2025v6n1p258

Two cases of clump formation after thawing of hematopoietic progenitor cell products for transplantation
type: item
description: While rare, clump formation has been described in the thawing of cryopreserved hematopoietic progenitor cell products intended for transplantation. When this occurs, it presents a significant challenge to the transplant team, potentially influencing the viability and safety of the product. Though the exact cause of clumping in thawed products remains unknown, studies have linked clump formation with the occurrence of adverse events. This report aimed to describe two cases of clump formation in thawed apheresis products observed in our processing laboratory, detailing the procedures followed and the outcomes achieved.
creator: Cecilia Gamba
creator: María del Rosario Silvestri
creator: Agustina Miguel
creator: Danila Labonia
creator: Nicolás Fernández Escobar
creator: Silvia Mariana Pizzi
creator: Daniel Díaz Sánchez
creator: Raquel Staciuk
creator: Silvina Laura Kuperman
rights: Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-07-23
publication date: 2025-07-23
volume: 6
number: 1
doi: 10.46765/2675-374X.2025v6n1e257

A case-control study on cryopreserved versus non-cryopreserved strategies for autologous hematopoietic cell transplantation in multiple myeloma
type: item
description: Background: Autologous hematopoietic cell transplantation (aHCT) is a standard treatment for Multiple Myeloma (MM). The classic practice is with cryopreservation of the peripheral blood stem cells (PBSC) in the period from collection to infusion, but non-cryopreserved storage at 4oC has demonstrated to be feasible and safe. Methods: Here we present a retrospective, case-control study comparing the outcomes in terms of engraftment in two centers in Uruguay, one with cryopreservation (Hospital Británico-HB) and the other with 4oC storage (Hospital Maciel-HM). Results: 69 patients were included during Oct 15, 2018 and Dec 23, 2023. Median age was 60 years old (32-72). The median of collected PBSC was 9.0 x 106/kg (range 2.7 - 32.3), and the median of PBSC infused was 5.4 x 106/kg, (range 2.7 - 10.8). The time to neutrophil engraftment was 10 days (range 6-12) in HM and 9 days (range 7-12) in HB (p=0.38). The time for platelet engraftment was 20 days (range 17-25) in HM and 19 days (range 15-30) in HB (p=0.14). There were no graft failures, and no treatment-related mortality was observed at 100 days. Conclusions: Both cryopreserved and non-cryopreserved strategies appear to achieve similar outcomes in terms of engraftment and safety. Non-cryopreservation could be a way to improve affordability and accessibility to aHCT in MM, particularly in resource-limited areas.
creator: Byron Figueroa
creator: Martin Ferrando
creator: Sebastian Galeano
creator: Gabriel Borelli
creator: Eloísa Riva
creator: Alberto Vásquez
creator: Carolina Oliver
creator: Rosanna De Giuda
creator: Silvia Pierri
creator: Leticia Martinez
creator: Melanie Isern
creator: Claudia Martinez
creator: Romina Urrutia
creator: Cristina Otero
creator: Victoria Irigoín
creator: Victoria Remedi
creator: Martina Perdomo
creator: María Mori
creator: Regis Gai
creator: Estefanía López
creator: Virginia Marcalain
creator: Camila Guidali
creator: Laura Bello
creator: Virginia Moraes
creator: Lourdes Viano
creator: Analía Olivera
creator: Carina Lamela
creator: Carla Ambrosini
creator: Silvia Pisano
creator: Juan Ferrari
creator: Jimena Prieto
creator: Raul Gabús
creator: Pablo Muxí
creator: Ana Inés Landoni
rights: Copyright (c) 2025 Byron Figueroa, Martin Ferrando, Sebastian Galeano, Gabriel Borelli, Eloísa Riva, Alberto Vásquez, Carolina Oliver, Rosanna De Giuda, Silvia Pierri, Leticia Martinez, Melanie Isern, Claudia Martinez, Romina Urrutia, Cristina Otero, Victoria Irigoín, Victoria Remedi, Martina Perdomo, María Mori, Regis Gai, Estefanía López, Virginia Marcalain, Camila Guidali, Laura Bello, Virginia Moraes, Lourdes Viano, Analía Olivera, Carina Lamela, Carla Ambrosini, Silvia Pisano, Juan Ferrari, Jimena Prieto, Raul Gabús, Pablo Muxí, Ana Inés Landoni https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-08-29
publication date: 2025-08-29
volume: 6
number: 1
starting page: 251
ending page: 251
doi: 10.46765/2675-374X.2025v6n1e251

The role of the pharmacy navigator in hematopoietic stem cell transplantation
type: item
description: Hematopoietic stem cell transplantation (HSCT) is a complex procedure that requires rigorous pharmacotherapeutic management. This study aimed to describe the role of the pharmacy navigator in HSCT at the Hospital das Cl.nicas of the Medical School of the Universidade de S.o Paulo. For the assessment of pharmacist activities in HSCT, a literature review was conducted, alongside direct observation of pharmaceutical activities in different HSCT phases at the service: pre-transplant, hospitalization, discharge, and outpatient follow-up. It was observed that the pharmacy navigator plays a crucial role, including medication reconciliation, dose adjustments, monitoring drug interactions and toxicities, and providing health education to patients and the multidisciplinary team. Pharmacotherapeutic follow-up contributed to reducing medication errors, improving treatment adherence, and ensuring safer administration of immunosuppressants and antimicrobials. In conclusion, the presence of a pharmacy navigator in HSCT is essential to optimize treatment, prevent complications, and enhance patients’ quality of life, consolidating this professional as a key member of the multidisciplinary healthcare team.
creator: Giovanna Fernandes Lago
creator: Carolina Ferreira dos Santos
creator: Andressa Pinheiro Diniz
creator: Leonardo Jun Otuyama
creator: Andrea Cassia Pereira Sforsin
creator: Vanusa Barbosa Pinto
rights: Copyright (c) 2025 Giovanna Fernandes Lago, Carolina Ferreira dos Santos, Andressa Pinheiro Diniz, Leonardo Jun Otuyama, Andrea Cassia Pereira Sforsin, Vanusa Barbosa Pinto https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-10-16
publication date: 2025-10-16
volume: 6
number: 1
doi: 10.46765/2675-374X.2025v6n1e279

Immune reconstitution inflammatory syndrome in HIV-negative patients with hematological malignancies and hematopoietic stem cell transplantation: A case series and a literature review
type: item
description: Immune reconstitution inflammatory syndrome (IRIS) is a potentially severe complication following the withdrawal of immunosuppressive agents, commonly studied in human immunodeficiency virus (HIV) positive patients. However, its impact on individuals with hematological malignancies and those undergoing hematopoietic stem cell transplants is less understood. This study aimed to establish diagnostic criteria for IRIS in these populations and assess its incidence and clinical progression. A cross-sectional, prospective observational study was conducted with 159 chemotherapy patients and 96 hematopoietic stem cell transplant recipients. IRIS diagnosis criteria were derived from a literature review of 70 studies, and patients were monitored for 11 months. The review identified key IRIS diagnostic criteria, including paradoxical clinical worsening, antimicrobial refractoriness, and inflammatory signs following immunosuppressive therapy. Most IRIS cases were linked to pathogens like Mycobacterium, Candida spp., and Aspergillus spp. Among our patients, three cases of IRIS were identified: one related to the Bacillus Calmette-Guérin (BCG) vaccine, another with neutrophil recovery, and the third with chronic disseminated candidiasis. Treatment with corticosteroids and antimicrobial therapy allowed continued chemotherapy without impacting the underlying disease’s outcomes. IRIS is an important complication in hematological and stem cell transplant patients. Early recognition and appropriate treatment, including corticosteroids and antimicrobial therapy, are critical for successful management and uninterrupted cancer treatment.
creator: Livia Santiago de Paula
creator: Giovanni Luis Breda
creator: Rafael Mialski Fontana
rights: Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-08-26
publication date: 2025-08-26
volume: 6
number: 1
starting page: 253
ending page: 253
doi: 10.46765/2675-374X.2025v6n1p253

Haploidentical Hematopoietic Stem-cell Transplant for High-Risk Acute Myeloid Leukemia in a Kidney Transplant Recipient: Case Report
type: item
description: Solid organ transplantation is associated with a higher incidence of malignancies. Among them, acute myeloid leukemia has high morbidity and mortality, and its cure is only possible through allogeneic hematopoietic stem cell transplantation for high-risk disease. Case report: A 32-year-old female who underwent a kidney transplant eight years before was diagnosed with high-risk acute myeloid leukemia. She underwent induction therapy with “7+3”, achieving complete remission with measurable residual disease detectable by flow cytometry. She then underwent a myeloablative haploidentical allogeneic transplant, achieving complete remission, free of graft-versus-host disease, with a functioning renal graft.
creator: Hercules Amorim Mota Segundo
creator: Ana Vitoria Magalhães Chaves
creator: Thays Araújo Freire de Sá
creator: Karine Sampaio Nunes Barroso
creator: Raimundo Messias de Araújo Filho
creator: Paula Frassinetti Castelo Branco Camurça Fernandes
creator: Fernando Barroso Duarte
rights: Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-06-13
publication date: 2025-06-13
volume: 6
number: 1
starting page: 264
ending page: 264
doi: 10.46765/2675-374X.2025v6n1p264

The Effectiveness of the Multiprofessional Approach in the Pediatric Rehabilitation of Chronic GVHD: The Specific Contribution of Occupational Therapy
type: item
description: Este estudo relata o processo de reabilitação em terapia ocupacional de uma criança de dois anos de idade com Doença do Enxerto contra o Hospedeiro Crônica (cGVHD), afetando múltiplos órgãos e articulações, impactando seu desenvolvimento neuropsicomotor (NPMD) e funcionalidade. O método utilizado foi o relato de caso, respeitando os protocolos éticos. A avaliação incluiu a Análise Observacional dos Marcos do NPMD e a Escala de Avaliação Funcional para GVHD Crônica (NIH). Com base nos resultados, utilizamos a Classificação Internacional de Funcionalidade, Incapacidade e Saúde para Crianças e Jovens (ICF-CJ) para categorizar os objetivos das intervenções terapêuticas. A intervenção seguiu quatro etapas: avaliação inicial, definição de objetivos, aplicação do Brinquedo Terapêutico Habilitador de Funções Fisiológicas (TP) e reavaliações periódicas. Após 27 sessões, houve melhora na amplitude de movimento das articulações afetadas, aumento da resistência respiratória e avanços no NPMD, incluindo deambulação e habilidades motoras finas, como alimentação. Os resultados demonstram a eficácia da terapia ocupacional na recuperação funcional e na promoção da qualidade de vida. Conclui-se que a intervenção precoce, integrada a uma equipe multidisciplinar, é essencial para minimizar os impactos da DECHc, prevenir sequelas e favorecer o desenvolvimento infantil.
creator: Natasha Santos Lemes
creator: Adriana Mello Rodrigues
creator: Dayane Regina dos Santos
rights: Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-06-04
publication date: 2025-06-04
volume: 6
number: 1
starting page: 252
ending page: 252
doi: 10.46765/2675-374X.2025v6n1p252

X linked- ALD: Should Loes score be the only benchmark for HSCT eligibility?
type: item
description: Hematopoietic stem cell transplant(HSCT) is the only modality that, if performed in the early- stages of cerebral X-linked adrenoleukodystrophy(X-ALD) can lead to good outcomes. Loes- score, calculated based on the findings of the magnetic resonance imaging(MRI) of the brain, helps in the selection of patients for HSCT. As per recommendations, the Loes-score should be <10 for a patient to be eligible for HSCT. Here we report a child of cerebral X-ALD with Loes of 12, but a good neurological function score(NFS), who was treated with HSCT, and had good outcomes. It is therefore important to utilize other parameters along with the Loes score, in selecting patients for HSCT in X-ALD.
creator: Aditya Kumar Gupta
creator: Pavit Singh
creator: Parvathy KN
creator: Atin Kumar
creator: Gargi Das
creator: Sayoni Roy Chowdhury
creator: Jagdish Prasad Meena
creator: Biswaroop Chakrabarthy
creator: Prashant Jauhari
creator: Rachna Seth
creator: Sheffali Gulati
rights: Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-05-06
publication date: 2025-05-06
volume: 6
number: 1
starting page: 250
ending page: 250
doi: 10.46765/2675-374X.2025v6n1p250

Updates on the management of Multiple Myeloma
type: item
description: Multiple Myeloma (MM) is a mature hematological neoplasm characterized by histological infiltration (bone marrow and/or extramedullary plasmacytomas) by clonal plasma cells and the presence of one or more defining events, including anemia, renal impairment, osteolytic lesions, and hypercalcemia. The management of MM has drammaticaly evolved over the past few years. However, new drugs are not available in the Brazilian public health service and treatment is still a challenge, especially in the relapsed/refractory setting. We herein summarize the updates in MM management and make recommendations for care in an optimal scenario and in the Brazilian public health service.
creator: Sérgio Parente Filho
creator: Jacqueline Holanda de Souza Souza
creator: Germana Franck de Souza Bastos Rocha
creator: João Paulo Vasconcelos
creator: Karine Sampaio Nunes Barroso
creator: Beatriz Stella Gomes de Souza Pitombeira Araújo
creator: Livia Andrade Gurgel
creator: Rafael da Nóbrega de Alencar
creator: Lucas Freire Castelo
creator: Fernando Barroso Duarte
rights: Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-01-22
publication date: 2025-01-22
volume: 6
number: 1
starting page: 249
ending page: 249
doi: 10.46765/2675-374X.2025v6n1p249

Guidelines for the Diagnosis and Management of Paroxysmal Nocturnal Hemoglobinuria (PNH) at Hospital Universitário Walter Cantídio.
type: item
description: Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare and poorly understood clonal disease in our region. It is caused by somatic mutations in the PIGA gene on the X chromosome. Such mutations result in the absence of GPI production, which is an anchoring structure for proteins like CD55 and CD59 that protect red blood cells from lysis mediated by the complement system. PNH presents a diverse clinical course that includes intravascular hemolysis, thrombosis, and cytopenias. Following the advent of the humanized monoclonal antibody Eculizumab, which inhibits the C5 portion of the complement system, thereby preventing the destruction of red blood cells by the membrane attack complex, there has been a significant change in the treatment of PNH and in the lives of its patients. This study aims to present the guidelines for the diagnosis and management of patients with PNH followed at a reference public hospital in Ceará, Brazil.
creator: Rafaela Pitombeira
creator: Fernando Duarte
rights: Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY https://creativecommons.org/licenses/by/4.0
license: https://creativecommons.org/licenses/by/4.0
date: 2025-07-01
publication date: 2025-07-01
volume: 6
number: 1
starting page: 256
ending page: 256
doi: 10.46765/2675-374X.2025v6n1p256